COCRYSTAL PHARMA INC (COCP) Stock News

USA - NASDAQ:COCP - US19188J4094 - Common Stock

1.1 USD

+0.09 (+8.91%)

Last: 11/7/2025, 8:00:01 PM

1.08 USD

-0.02 (-1.82%)

After Hours: 11/7/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

COCP Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

2 months ago - By: Benzinga - Mentions: ONCY AHG CHEK HSDT ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

2 months ago - By: Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

2 months ago - By: Benzinga - Mentions: GRI IVA ADXN ANEB ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

2 months ago - By: Cocrystal Pharma, Inc.

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

a year ago - By: BusinessInsider

News Image

COCP Stock Earnings: Cocrystal Pharma Misses EPS for Q2 2024

a year ago - By: InvestorPlace

COCP Stock Earnings: Cocrystal Pharma Misses EPS for Q2 2024

1 years ago - By: InvestorPlace

COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q1 2024

2 months ago - By: Cocrystal Pharma, Inc.

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

3 months ago - By: The Motley Fool

Cocrystal Pharma Narrows Loss in Q2

3 months ago - By: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

5 months ago - By: Cocrystal Pharma, Inc.

Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference

2 years ago - By: InvestorPlace

COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023

2 years ago - By: BusinessInsider

News Image

COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023

7 months ago - By: Cocrystal Pharma, Inc.

Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

7 months ago - By: Cocrystal Pharma, Inc.

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

8 months ago - By: Virtual Investor Conferences - Mentions: CGTX AVCN.CA NGEN.CA FBLG ...

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

8 months ago - By: Virtual Investor Conferences - Mentions: CGTX AVCN.CA NGEN.CA FBLG ...

Life Sciences Investor Forum Agenda Announced for March 13th

10 months ago - By: Cocrystal Pharma, Inc.

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

a year ago - By: Cocrystal Pharma, Inc.

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

a year ago - By: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

a year ago - By: Cocrystal Pharma, Inc.

New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows

1 years ago - By: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

2 years ago - By: Cocrystal Pharma, Inc.

Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

2 years ago - By: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

2 years ago - By: Cocrystal Pharma, Inc.

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

2 years ago - By: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

2 years ago - By: Cocrystal Pharma, Inc.

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast